Company intelligence / Profile preview
Tinos Therapeutics
Providence, Rhode Island, United Statestinostx.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Tinos Therapeutics has developed the Epi-CODE™ RNA Platform for creating novel RNA-based therapeutics targeting hard-to-treat cancers. Preclinical research demonstrates strong efficacy in mouse models, showing tumor growth inhibition and increased survival rates. The company’s immediate focus is on securing funding and advancing into human clinical trials.
- Therapeutic areas
- Oncology
- Modalities
- RNA therapeutics (specifically leveraging RNA modification technology)
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Tinos Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Tinos Therapeutics.